Ashok Srivastava

Clinical Officer, Car-t Cell Therapy Relapsed Refractory Leukemia Lymphoma @Autolus Therapeutics

London, GB

CAR-T cell therapy of lymphoma and leukemia.Highly active T cell therapies for cancer.An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic LeukemiaA Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Clinical and safety data review and BLA submissionSafety and efficacy of a CAR-T cell treatment targeting CD19, in adult patients with relapsed or refractory B cell Acute Lymphoblastic Leukemia.Pre-BLA meeting with FDAFile BLAFDA Inspection readiness

Nagasaki University

Doctor of Medicine - MD, School of Medicine, Nagasaki University, Nagasaki, Japan , Medicine

Rutgers University

Executive MBA, Pharmaceutical Business Management, Rutgers University, New Jersey, USA

School of Medicine Nagasaki University, Japan; All India Institute of Medical Science New Delhi India; Rutgers U. Business, NJ, USA;

MD, Ph.D., MBA, Medical Oncology and Hematology

Tufts University

Tufts Center for the Study of Drug Development , Tufts Center for the Study of Drug Development

Georgetown University School of Medicine

Fellwoship Clinical Pharmacology

All India Institute of Medical Sciences

Medicine

ESMO

Oncology

Harvard University

Artificial intelligence in Healthcare

Accreditation Council for Medical Affairs, New York, NY, Year, USA

Professional Certification in Medical Affairs Oncology Board , Oncology, Hematology and Immuno-Oncology- 2017

Harvard University

Clinical and Medical oncology, Medical Oncology at Dana Farber Cancer Center

University Hospital Kralovske Vinohrady at Prague Prague

Ph.D., Immunology, Onco-virology, Czechoslovak Acadamey of Medical Sciences, Prague, Czechoslovakia, Infectious Diseases

United Nations

Medical Officer, Pediatric Health Care in Europe